Health Care · Laboratory Analytical Instruments

CTKB Cytek Biosciences, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 183191585 filings
Russell 2000

CTKB at a glance

Cytek Biosciences, Inc. (CTKB, SEC CIK 1831915) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Cytek Biosciences, Inc. (CTKB) reported revenue of $201.5 million (up 0.5% from FY2024) and a net loss of $66.5 million.
  • As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding Cytek Biosciences, Inc. (CTKB) shares worth $253.2 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$201.5M
+0.5% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
26 funds
$253.2M · −2 vs prior quarter
Latest 8-K
Nov 4, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $53.2M, up 2% YoY from $52.3M, driven by service revenue $16.1M, up 13%
  • Gross margin 59% vs 53% YoY, product margin 61% vs 53%, service margin 53% vs 51%
  • Best performer: service revenue $16.1M, up $1.9M; weakest: product revenue $37.2M, down $1.0M
  • Cash, equivalents, restricted cash and marketable securities $256.3M vs $261.5M at December 31, 2025; operating cash used $5.8M
  • Near-term headwinds: biotech funding constraints, tariffs, export controls and potential NIH policy impacts on academic demand

Risk Factors

  • New export-control risk: January 15, 2025 U.S. license requirements now cover certain flow cytometers and cell sorters exported to China
  • Updated trade risk: Singapore and China tariff rates increased from 10% to 12.5%, potentially raising manufacturing costs
  • New cybersecurity exposure: November 2025 security incident affected employee personal information
  • Near-term demand risk: academic and government institutions generated 46% of revenue in Q3 2026, increasing exposure to NIH funding reductions
  • Liquidity risk: existing cash expected to fund operating expenses for at least 12 months from the filing date

AI summary of the CTKB 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Cytek announced financial results for the quarter ended September 30, 2026
  • Investors should review Exhibit 99.1 for revenue, profitability, cash flow and guidance details

Item EX-99.1: Item EX-99.1

  • Q3 revenue $53.2M, up 2%, with U.S. revenue up 12% and high-end instrument revenue up 11%
  • Recurring revenue $19.1M, reaching 36% of trailing-12-month revenue versus 33% previously, improving business visibility
Filed Sep 29, 2026Full analysis →

Item 5.03: Amendments to Articles of Incorporation or Bylaws

  • A&R Bylaws effective September 23, 2026, adopted unanimously by the board
  • Expanded disclosure, ownership, solicitation and certification requirements for stockholder proposals and director nominees
Filed Aug 24, 2026Full analysis →

Item 8.01: Other Events

  • Jury verdict favored Cytek on three of four asserted Beckman Coulter patent claims
  • $20 million lost-profit award and $36.11 million royalty award for one claim

Item 7.01: Regulation FD Disclosure

  • Jury verdict in Beckman Coulter patent infringement action, decided in the U.S. District Court for Delaware
  • Litigation outcome creates potential intellectual property, product availability and financial exposure for Cytek

AI summaries of CTKB 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for CTKB

Don't miss the next CTKB filing

  • Alerts as it files. A push when CTKB files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut CTKB, by share count.
  • Ask anything. An AI agent that reads every CTKB filing and answers with sources.

CTKB alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
McCombe William D.MNov 18, 2026-
McCombe William D.FNov 18, 2026$5.92
McCombe William D.MNov 18, 2026-
McCombe William D.FNov 18, 2026$5.92
McCombe William D.FNov 18, 2026$5.92
McCombe William D.MNov 18, 2026-
MUIR GLENN PMNov 18, 2026-
MUIR GLENN PMNov 18, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$193.0M$200.5M$201.5M
Gross Profit-$111.1M$104.5M
Operating Income--$20.5M-$40.4M
Net Income--$6.0M-$66.5M
Gross Margin-55.4%51.8%
Op. Margin--10.2%-20.0%
Net Margin--3.0%-33.0%
Balance Sheet
Total Assets$494.5M$499.5M$461.5M
Equity$393.1M$395.7M$341.7M
ROE--1.5%-19.5%
Cash Flow
Operating CF-$25.4M-$4.7M
CapEx$4.6M$3.5M$4.1M

Source: XBRL data in Cytek Biosciences, Inc. (CTKB)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate CTKB share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
CTKB shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202626$253.2M
Q2 202628$177.5M
Q1 202630$211.1M
Q4 202528$233.3M
Q3 202528$153.1M
Q2 202526$145.4M
Q1 202524$105.2M
Q4 202421$154.8M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 211 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

CTKB filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 20, 2026--
4Nov 20, 2026--
4Nov 20, 2026--
4Nov 20, 2026--
4Nov 20, 2026--
4Nov 20, 2026--
4Nov 12, 2026--
10-QNov 4, 2026Analysis
8-KNov 4, 2026Analysis-
8-KSep 29, 2026Analysis-
8-KAug 24, 2026Analysis-
4Aug 20, 2026--
4Aug 20, 2026--
4Aug 20, 2026--
4Aug 20, 2026--
4Aug 20, 2026--
4Aug 20, 2026--
4Aug 12, 2026--
8-KAug 5, 2026Analysis-
10-QAug 5, 2026Analysis
SC 13GAug 4, 2026-
8-KJul 15, 2026Analysis-
8-KJun 25, 2026Analysis-
8-KJun 16, 2026Analysis-
4Jun 16, 2026--

Related Health Care companies

All Health Care →

CTKB SEC filings: frequently asked questions

Which institutions hold CTKB stock?

As of September 30, 2026, the largest Cytek Biosciences, Inc. (CTKB) holders among the 13F filers tracked by SignalX were BlackRock ($72.6 million), Millennium Management ($43.4 million), Vanguard Capital Management LLC ($29.1 million), Dimensional Fund Advisors ($15.3 million), State Street Corp ($15.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was CTKB's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Cytek Biosciences, Inc. (CTKB) reported revenue of $201.5 million (up 0.5% from FY2024) and a net loss of $66.5 million. The figures come from the XBRL data in the 10-K.

What did CTKB report in its latest 8-K?

Cytek Biosciences, Inc. (CTKB) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Cytek announced financial results for the quarter ended September 30, 2026.

What are the latest CTKB SEC filings?

Cytek Biosciences, Inc. (CTKB) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 20, 2026.

What is CTKB's SEC CIK number?

Cytek Biosciences, Inc. (CTKB)'s SEC Central Index Key (CIK) is 1831915. EDGAR lists every CTKB filing under that number.

Ask anything about CTKB

The research agent reads CTKB's filings, financials, insider trades and 13F holders, then answers with sources.